Tag Archives: Mark Massaro

Meridian Bioscience (VIVO) Gets a Sell Rating from Canaccord Genuity

In a report released today, Mark Massaro from Canaccord Genuity maintained a Sell rating on Meridian Bioscience (VIVO – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $8.76, close to its 52-week low

Quidel (QDEL) Gets a Buy Rating from Canaccord Genuity

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Quidel (QDEL – Research Report) yesterday and set a price target of $75.00. The company’s shares closed last Monday at $64.19. According to TipRanks.com, Massaro is a top 100 analyst

T2 Biosystems (TTOO) Receives a Rating Update from a Top Analyst

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on T2 Biosystems (TTOO – Research Report) today and set a price target of $3.00. The company’s shares closed last Monday at $1.95. According to TipRanks.com, Massaro is a top 100

Orasure Technologies (OSUR) Gets a Hold Rating from Canaccord Genuity

Canaccord Genuity analyst Mark Massaro maintained a Hold rating on Orasure Technologies (OSUR – Research Report) yesterday and set a price target of $8.00. The company’s shares closed last Monday at $8.57. According to TipRanks.com, Massaro is a top 100

Guardant Health (GH) Receives a Rating Update from a Top Analyst

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $125.00. The company’s shares closed last Monday at $64.20. According to TipRanks.com, Massaro is a top 100

Canaccord Genuity Keeps Their Buy Rating on Quanterix (QTRX)

In a report released yesterday, Mark Massaro from Canaccord Genuity maintained a Buy rating on Quanterix (QTRX – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $19.29, close to its 52-week low of